RxNet is a free online community, uniting scientists from the fields of chemistry, biochemistry and beyond to further the ever-booming industry of drug discovery and development.

On RxNet, in partnership with our associated journals, Future Drug Discovery, Future Medicinal Chemistry, Pharmaceutical Patent Analyst and Therapeutic Delivery, we aim to provide current and exciting research and information on all aspects of the drug discovery pipeline. This includes: novel small molecules, biopharmaceuticals, vaccine development, industry updates and preclinical and Phase I studies – from lead to licence. We do this by publishing the latest news and up-to-date research from the field, as well as expert interviews and opinion, peer-reviewed journal articles and exclusive multimedia content.

RxNet members can connect and collaborate with industry leaders and academic experts as well as share their own research and opinion without the wait. 

Medicinal chemistry/drug discovery pipeline

Why should you join?

First and foremost, you should do so because, by joining the network and sharing your news and knowledge, you will be contributing towards the development of this exciting field. This network also gives you the opportunity to connect with your peers and help gain knowledge and connections that may be useful to your work. RxNet is largely based on content generated by the network’s users and is designed to provide experts with a platform to collaborate, showcase their work and share news and their perspectives on the field.

Key points

  • Free to join
  • Fast access to editor- and user-generated news, discussion and opinion on key topics
  • Share your own news and views in posts, videos and panels
  • Network with your peers
  • Exclusive free access to selected journal articles published by Future Science Group
  • Weekly newsletter keeping you up to date

Did you know?

By joining RxNet, you also get free access to our partner sites. Simply sign in with your RxNet username and password and gain access to:

RegMedNet provides free educational webinars, expert opinion and insight, and exclusive peer-reviewed journal articles, as well as the latest news and advances from every step in the regenerative medicine and cell therapy pipeline, from development, clinical trial and manufacture to regulation and commercialization. 

Access your free account>>

3DMedNet unites the diverse 3D printing in medicine community, covering 3D printed pharmaceuticals, prosthetics, implants, medical devices and bioprinted tissue via expert opinion and insight, and exclusive peer-reviewed journal articles, as well as the latest news and advances.

Access your free account>>

The Evidence Base™ covers the latest news, opinion and insight into the collection and application of real-world data to real-world problems, including real-world evidence, health economics, comparative effectiveness research, patient-centered decision making and much more.

Access your free account>>

Who is RxNet?

There are plenty of wonderful people working behind the scenes to help this network operate, but the core team is:

  • Zoe Campbell, Digital Editor & Community Manager (z.campbell@rx-network.com)
    Zoe knows all there is to know about the site and can help you if you have any questions about using the network. You can find more about Zoe by checking out her profile, and can find her posts here.
  • Harriet Wall, Commissioning Editor, Future Medicinal Chemistry & Pharmaceutical Patent Analyst (h.wall@future-science.com)
    Harriet is the Commissioning Editor for two of our partner journals. For any information on submitting to either of these journals, Harriet should be your point of contact.
  • Dionne Murray,  Head of Advertising (d.murray@futuremedicine.com)
    As a member of our business development team, Dionne is the primary contact for all things related to sponsorship and advertising. Please drop her an email if you wish to discuss commercial opportunities available on RxNet. If you would like to know more about using RxNet please see the user guide or speak to the Community Manager.